Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03718091 · ClinicalTrials.gov registry record · Phase 2
M6620 (VX-970) in Selected Solid Tumors
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT03718091: Completed Phase 2 study, sponsored by Massachusetts General Hospital.
NCT03718091 is a Phase 2 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 30 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03718091, a Phase 2 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
This research study is studying a drug called M6620 as a possible treatment for advanced solid tumor.
Primary Outcome
Changes in the levels of Phospho-Chk1 in biopsy specimens of patients treated with M6620 monotherapy from baseline to cycle 1 day 15. This is a pharmacodynamic endpoint to evaluate target engagement. Results are in percent change of Phospho-Chk1 levels from baseline versus on-treatment biopsies.
Interventions
- DRUG M6620
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2019-01-08 |
| Est. Completion | 2020-07-08 |
| Phase | Phase 2 |
What the finished NCT03718091 record still lists
NCT03718091 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 1 intervention - of which M6620 is the first listed.
NCT03718091 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03718091 about?
NCT03718091 is a clinical study titled "M6620 (VX-970) in Selected Solid Tumors". This research study is studying a drug called M6620 as a possible treatment for advanced solid tumor.
What is the current status of trial NCT03718091?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2019-01-08. Estimated completion is 2020-07-08.
What interventions are being tested in trial NCT03718091?
The interventions under investigation include: M6620 (DRUG).
Who is sponsoring clinical trial NCT03718091?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03718091's enrollment target sits among peer trials
30 1582nd of 2000 higher than 332 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI